Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 33


Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.

Bollito E, De Luca S, Cicilano M, Passera R, Grande S, Maccagnano C, Cappia S, Milillo A, Montorsi F, Scarpa RM, Papotti M, Randone DF.

Anal Quant Cytol Histol. 2012 Apr;34(2):96-104.


Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients.

Goode RR, Marshall SJ, Duff M, Chevli E, Chevli KK.

Prostate. 2013 Jan;73(1):48-53. doi: 10.1002/pros.22538. Epub 2012 May 14.


Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.

Ferro M, Bruzzese D, Perdonà S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, Di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V, Terracciano D.

Clin Chim Acta. 2012 Aug 16;413(15-16):1274-8. doi: 10.1016/j.cca.2012.04.017. Epub 2012 Apr 20.


The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy.

Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, Forgues A, Robert G, Vacherot F, Loric S, Allory Y, Ruffion A, de la Taille A.

BJU Int. 2012 Jul;110(1):43-9. doi: 10.1111/j.1464-410X.2011.10682.x. Epub 2012 Jan 5.


Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.

Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):100-5. doi: 10.1038/pcan.2011.52. Epub 2011 Nov 1.


A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.

BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.


The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance.

van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, Remzi M, Marberger M.

BJU Int. 2012 Feb;109(3):360-6. doi: 10.1111/j.1464-410X.2011.10377.x. Epub 2011 Aug 26.


The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.

Adam A, Engelbrecht MJ, Bornman MS, Manda SO, Moshokoa E, Feilat RA.

BJU Int. 2011 Dec;108(11):1728-33. doi: 10.1111/j.1464-410X.2011.10202.x. Epub 2011 Apr 20.


Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions.

de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, Gontero P, Mottaz A, Haese A.

J Urol. 2011 Jun;185(6):2119-25. doi: 10.1016/j.juro.2011.01.075. Epub 2011 Apr 15.


Urinary PCA3 score predicts prostate cancer multifocality.

Vlaeminck-Guillem V, Devonec M, Colombel M, Rodriguez-Lafrasse C, Decaussin-Petrucci M, Ruffion A.

J Urol. 2011 Apr;185(4):1234-9. doi: 10.1016/j.juro.2010.11.072. Epub 2011 Feb 22.


Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy.

Ochiai A, Okihara K, Kamoi K, Iwata T, Kawauchi A, Miki T, Fors Z.

Int J Urol. 2011 Mar;18(3):200-5. doi: 10.1111/j.1442-2042.2010.02711.x.


Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance.

Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, Nicolaiew N, Terry S, Allory Y, Loric S, Salomon L, Vacherot F, de la Taille A.

Eur Urol. 2011 Mar;59(3):422-9. doi: 10.1016/j.eururo.2010.11.044. Epub 2010 Dec 8.


PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols.

Liss MA, Santos R, Osann K, Lau A, Ahlering TE, Ornstein DK.

World J Urol. 2011 Oct;29(5):683-8. doi: 10.1007/s00345-010-0623-6. Epub 2010 Dec 9.


Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.

Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budäus L, Fisch M, Huland H, Graefen M, Haese A.

Eur Urol. 2011 Jan;59(1):96-105. doi: 10.1016/j.eururo.2010.10.024. Epub 2010 Oct 20.


PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population.

Nyberg M, Ulmert D, Lindgren A, Lindström U, Abrahamsson PA, Bjartell A.

Scand J Urol Nephrol. 2010 Dec;44(6):378-83. doi: 10.3109/00365599.2010.521187. Epub 2010 Oct 21.


A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.

Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX, Yao XD.

Prostate. 2011 May 15;71(7):700-10. doi: 10.1002/pros.21286. Epub 2010 Oct 18.


Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.

Perdonà S, Cavadas V, Di Lorenzo G, Damiano R, Chiappetta G, Del Prete P, Franco R, Azzarito G, Scala S, Arra C, De Sio M, Autorino R.

Eur Urol. 2011 Jan;59(1):81-7. doi: 10.1016/j.eururo.2010.09.036. Epub 2010 Oct 14.


PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J.

J Urol. 2010 Nov;184(5):1947-52. doi: 10.1016/j.juro.2010.06.098. Epub 2010 Sep 17.


Supplemental Content

Support Center